The
Magnolol
apoptosis
hepatocellular carcinoma
radiation
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
09
04
2020
revised:
15
04
2020
accepted:
17
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Radiation (RT) induced ERK/NF-κB in hepatocellular carcinoma (HCC) has been reported in our previous works; it weakens the toxicity of RT or triggers a radioresistance effect. Thus, combining RT with a suitable NF-κB inhibitor may sensitize HCC to RT. Magnolol, a bioactive compound, was known to have anti-inflammatory and anti-tumor functions. Here, we aimed to investigate whether magnolol may enhance anti-HCC efficacy of RT in vivo. We established a Hep3B bearing mouse to evaluate the efficacy of the combination treatment of magnolol and RT. Most significantly, tumor volume and tumor weight inhibition was found in the combination group. Tumor immunohistochemistry staining also illustrated the suppression of RT-induced ERK/NF-κB-related proteins expression by magnolol. In addition, intrinsic apoptosis-related proteins, such as caspase-3 and -9, were markedly increased in the combination group. Magnolol may effectively enhance anti-HCC ability of RT by downregulating the expression of ERK/NF-κB-related proteins and increasing the expression of apoptosis-related proteins.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Radiation (RT) induced ERK/NF-κB in hepatocellular carcinoma (HCC) has been reported in our previous works; it weakens the toxicity of RT or triggers a radioresistance effect. Thus, combining RT with a suitable NF-κB inhibitor may sensitize HCC to RT. Magnolol, a bioactive compound, was known to have anti-inflammatory and anti-tumor functions. Here, we aimed to investigate whether magnolol may enhance anti-HCC efficacy of RT in vivo.
MATERIALS AND METHODS
METHODS
We established a Hep3B bearing mouse to evaluate the efficacy of the combination treatment of magnolol and RT.
RESULTS
RESULTS
Most significantly, tumor volume and tumor weight inhibition was found in the combination group. Tumor immunohistochemistry staining also illustrated the suppression of RT-induced ERK/NF-κB-related proteins expression by magnolol. In addition, intrinsic apoptosis-related proteins, such as caspase-3 and -9, were markedly increased in the combination group.
CONCLUSION
CONCLUSIONS
Magnolol may effectively enhance anti-HCC ability of RT by downregulating the expression of ERK/NF-κB-related proteins and increasing the expression of apoptosis-related proteins.
Identifiants
pubmed: 32606148
pii: 34/4/1789
doi: 10.21873/invivo.11973
pmc: PMC7439903
doi:
Substances chimiques
Biphenyl Compounds
0
Lignans
0
NF-kappa B
0
Radiation-Sensitizing Agents
0
magnolol
001E35HGVF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1789-1796Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Int J Mol Sci. 2020 Jan 29;21(3):
pubmed: 32013255
Biomed Res Int. 2015;2015:363671
pubmed: 26539482
Environ Toxicol. 2020 Feb;35(2):167-175
pubmed: 31714653
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604
pubmed: 31439937
Int J Mol Sci. 2019 May 23;20(10):
pubmed: 31126017
Anticancer Res. 2014 Nov;34(11):6333-8
pubmed: 25368232
Crit Rev Oncol Hematol. 2006 Nov;60(2):89-98
pubmed: 16860993
Hepatology. 2019 Jun;69(6):2533-2545
pubmed: 30805950
Cancer Lett. 2006 Jan 18;231(2):158-68
pubmed: 16399220
Anticancer Res. 2018 Apr;38(4):2119-2125
pubmed: 29599330
Oncol Lett. 2017 Jul;14(1):461-467
pubmed: 28693192
J Biomed Sci. 2016 Dec 7;23(1):88
pubmed: 27923354
Oncol Rep. 2017 Feb;37(2):1036-1044
pubmed: 28000898
Neoplasia. 2012 Oct;14(10):893-904
pubmed: 23097624
Cancer. 1992 Aug 1;70(3):709-13
pubmed: 1320454
Int J Mol Sci. 2018 Dec 03;19(12):
pubmed: 30513990
J Clin Transl Hepatol. 2019 Jun 28;7(2):183-190
pubmed: 31293919
Biomed Pharmacother. 2017 Sep;93:1025-1032
pubmed: 28732393
Oncotarget. 2016 Dec 20;7(51):85450-85463
pubmed: 27863427
In Vivo. 2018 Nov-Dec;32(6):1361-1368
pubmed: 30348689
Biomed Pharmacother. 2019 Aug;116:109032
pubmed: 31163381
Biomed Pharmacother. 2020 Jun;126:110054
pubmed: 32145588
Sci Rep. 2017 Oct 25;7(1):14043
pubmed: 29070894
Int J Mol Sci. 2020 Mar 09;21(5):
pubmed: 32182776